The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...

amycretin and [a] once-weekly GIP/GLP-1 co-agonist. Moving to obesity and the first half of '25, we are now expecting to submit ... semaglutide (25 milligrams) for people with obesity to the U.S ...

The new results with a once-weekly subcutaneous injection of amycretin – which is also being developed in a daily oral formulation – show that the combined GLP-1 and amylin agonist achieved up ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. The Denmark-based company performed pretty well, leading to a post-earnings jump ...

Invest in the best stocks under $50 with Interactive Brokers for fast trade execution. You don’t need thousands of dollars in the bank to get started investing. Just $50, or less, can help you ...

NVS and ABBV announce small M&A deals. FDA approves the expanded use of PFE and RHHBY's drugs. Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...